Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionGroupama Asset Managment
Latest Disclosed Ownership36,767 shares
Latest Disclosed Value $ 12,165,097
Groupama Asset Managment reports 2.48% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 22, 2026 - Groupama Asset Managment filed a 13F-HR form disclosing ownership of 36,767 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $10,504,332 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 27, 2026 disclosing 35,878 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 2.48% during the quarter. The current value of the position is $9,577,804 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-22 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 36,767 889 2.48 12,165 -14.73 0.1777
2026-02-27 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,878 3,796 11.83 14,267 -23.34 0.2089
2025-12-01 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32,082 -16,303 -33.69 18,610 5.96 0.2727
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,385 -72,032 -59.82 17,562 40.42 0.2905
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 120,417 91,967 323.26 12,508 50.29 0.2499
2025-02-12 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,450 7,065 33.04 8,323 35.74 0.1701
2024-11-15 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,385 -2,849 -11.76 6,131 4.13 0.1593
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,234 21,978 974.20 5,889 80.95 0.0799
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,256 -15,061 -86.97 3,255 -1.84 0.0593
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,317 17,317 3,316 0.0864
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.